Trials / Unknown
UnknownNCT01993784
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety and efficacy of different dosage of Nimotuzumab in second or late- line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nimotuzumab |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-03-01
- Completion
- 2014-06-01
- First posted
- 2013-11-25
- Last updated
- 2013-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01993784. Inclusion in this directory is not an endorsement.